Ocugen, Inc.

Equities

OCGN

US67577C1053

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:30:47 2024-03-28 am EDT 5-day change 1st Jan Change
1.725 USD -3.09% Intraday chart for Ocugen, Inc. +28.36% +199.13%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Markets Steady -2- DJ
Sector Update: Health Care Stocks Steady Premarket Monday MT
Sector Update: Health Care Stocks Ease Late Afternoon MT
Ocugen Stock Rallies After Appeals Court Dismisses Allegations of Misleading Shareholders MT
Ocugen, Inc. Announces Ramesh Kumar Will Not Stand for Re-Election as Director CI
North American Morning Briefing : Stock Futures -2- DJ
Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer CI
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 CI
North American Morning Briefing : Inflation Data -2- DJ
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST CI
Transcript : Ocugen, Inc. - Special Call
HC Wainwright Adjusts Price Target on Ocugen to $7 From $5, Maintains Buy Rating MT
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board CI
Ocugen, Inc. Gains FDA Alignment on Key Aspects of OCU400 ?Modifier Gene Therapy?Pivotal Phase 3 Study Design CI
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410?Modifier Gene Therapy?For Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration CI
Ocugen Begins Dosing in Phase 1/2 Trial of Stargardt Disease Therapy Candidate MT
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST --Modifier Gene Therapy-- for Stargardt Disease CI
Transcript : Ocugen, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Ocugen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday MT
Ocugen, Inc. Announces Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH NIAID Project NextGen for Inclusion in Clinical Trials CI
Ocugen Says Mucosal Vaccine Candidate Selected for Clinical Trials by US NIAID MT
Ocugen, Inc. Appoints Connie Collingsworth to the Business Advisory Board CI
Ocugen, Inc. Announces Executive Changes CI
Ocugen Says Modifier Gene Therapy Product 'Safe, Well-Tolerated' for Patients With Genetic Eye Disorders MT
Chart Ocugen, Inc.
More charts
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. The Company's technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. It is developing COVAXIN, which is a whole-virion inactivated intramuscular COVID-19 vaccine candidate for the North American market. It is also developing a inhaled mucosal vaccine platform, which includes OCU500, a bivalent COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and bivalent COVID-19 vaccine. Its modifier gene therapy platform is focused on addressing various retinal diseases, including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), and Stargardt disease, with a single mutation-agnostic therapy.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.78 USD
Average target price
6.333 USD
Spread / Average Target
+255.81%
Consensus
  1. Stock
  2. Equities
  3. Stock Ocugen, Inc. - Nasdaq
  4. News Ocugen, Inc.
  5. Ocugen's Study of COVID-19 Vaccine Put on Clinical Hold After Issues at Bharat Biotech Facility; Shares Fall Pre-Bell